- Home
- /
- Growth Factor / Endocrine Research
- /
- Tesamorelin
SKU
AZ-TESA-10 / AZ-TESA-20
Tesamorelin
In Stock
From $76.00
You save (%)
Fulfillment Timing Based on Inventory and Account Status.
Tesamorelin
HPLC Certified
CAS #
218949-48-5
M.W.
5135.9
Formula
C221H366N72O67S
- PURITY
- ≥99%
RUO
- (Research Use Only)
Specs:
- Amount: 10mg / 20mg | Format: Lyophilized Powder | Container: 3mL Vial | Storage: 2-8°C | Type: Modified Peptide Analog | Research Alias: TESA | Research Category: GHRH Analog Research
What Is Tesamorelin?
Tesamorelin is a synthetic 44-amino acid analogue of human growth hormone-releasing hormone (GHRH). Its structure reproduces the full GHRH(1-44) sequence with a trans-3-hexenoyl group attached at the N-terminus, a modification that slows enzymatic degradation and extends plasma half-life relative to unmodified GHRH. The compound is one of the most heavily documented GHRH analogues in the published scientific record, with a literature base spanning adipose tissue biology, hepatic lipid metabolism, the GH/IGF-1 signaling axis, peripheral nerve regeneration models, and neurochemical research.
Tesamorelin is studied as a receptor-level tool rather than as a direct hormone substitute. Because it acts upstream at the GHRH receptor, research protocols using tesamorelin preserve endogenous pulsatile growth hormone release patterns instead of overriding them, which is why it appears frequently in study designs comparing GHRH analogues against exogenous growth hormone administration.
AZOTH supplies tesamorelin synthesized to 99%+ purity for licensed researchers and laboratory professionals. This material is intended exclusively for in vitro and laboratory research use.
How Does Tesamorelin Work? Several Mechanisms Studied
The research literature describes tesamorelin activity through several connected signaling pathways rather than a single isolated mechanism.
GHRH Receptor Binding and Pulsatile Signaling
Tesamorelin binds the GHRH receptor on anterior pituitary somatotroph cells, the same receptor engaged by native GHRH. Receptor binding initiates cyclic AMP accumulation and downstream signaling that governs growth hormone synthesis and release. Because the compound works through the physiological receptor pathway, research models using tesamorelin retain the pulse frequency and amplitude characteristics of native GH secretion, a design property that distinguishes GHRH analogue studies from studies administering recombinant growth hormone directly.
Structural Modification and Plasma Stability
Native GHRH is degraded quickly by dipeptidyl peptidase-4 at the N-terminus. The trans-3-hexenoyl group added to position one of the tesamorelin sequence limits this cleavage and extends circulating half-life. This structural feature is the basis for tesamorelin’s use in longer-duration study protocols where sustained receptor engagement is required.
IGF-1 Axis Activity
Growth hormone released downstream of GHRH receptor activation stimulates hepatic insulin-like growth factor 1 (IGF-1) production. Published research using tesamorelin has measured IGF-1 as a primary biochemical readout of GH axis engagement, and the GH/IGF-1 axis is the pathway through which most secondary research endpoints in this literature are interpreted.
Adipose Tissue Lipid Signaling
Growth hormone signaling influences hormone-sensitive lipase activity and lipolytic pathways within adipocytes, with reported differences between visceral and subcutaneous fat depots. This depot-specific signaling behavior is a recurring subject in tesamorelin research and is the mechanistic basis for the body composition endpoints reported across the published trial record.
Product Specifications
| Specification | Detail |
| Compound | Tesamorelin |
| Classification | GHRH(1-44) analogue, synthetic peptide |
| Amino Acid Count | 44 |
| CAS Number | 901758-09-6 |
| Molecular Formula | C223H370N72O69S |
| Molecular Weight | 5195.908 g/mol |
| PubChem CID | 44147413 |
| Purity | 99%+ verified by HPLC |
| Format | Lyophilized powder |
| Vial Size | 5mg |
| Origin | Manufactured in the USA |
| Documentation | Certificate of Analysis available per batch |
Sequence (Three Letter):
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu, with a trans-3-hexenoyl group at the N-terminus.
Buy Tesamorelin Peptide for These Research Applications
Adipose Tissue and Body Composition Research
Visceral adipose tissue behaves differently from subcutaneous fat in its hormonal responsiveness, inflammatory profile, and metabolic activity. Tesamorelin appears throughout the published literature as an investigational tool in studies measuring depot-specific adipose tissue changes by CT and MRI imaging. Multicenter randomized trial data reported reductions in CT-measured visceral adipose tissue over 26 to 52 week study periods, with pooled phase III analysis quantifying the magnitude of that change against placebo controls. Researchers studying differential fat depot regulation reference this dataset as one of the more completely characterized GHRH analogue body composition records available.
Hepatic Lipid and Liver Fat Research
Liver fat accumulation is a research category with limited pharmacological tool compounds. A randomized, double-blind, multicentre trial published in 2019 measured liver fat content by MRI proton density fat fraction alongside paired liver histology, reporting changes in hepatic fat content and fibrosis stage progression across a 12-month study period. Separate analysis examined the relationship between visceral fat change and liver enzyme measurements. These datasets are referenced in research on the connection between visceral adiposity, free fatty acid flux, and hepatic steatosis.
Cardiometabolic Marker Research
Studies pairing body composition imaging with biochemical panels have examined whether adipose tissue change correlates with measurable shifts in lipid and inflammatory markers. Published analysis reported associations between the degree of visceral adipose tissue reduction and changes in triglyceride levels, HDL cholesterol, and insulin resistance indices. Additional work measured inflammatory marker behavior against visceral adipose reduction in the same research populations. Predictor analysis has also examined which baseline characteristics correlate with measured response magnitude.
Peripheral Nerve Regeneration Research
Nerve regeneration is constrained by the slow rate of axonal outgrowth and the progressive atrophy of denervated Schwann cells and muscle tissue before reinnervation occurs. Review literature has assessed growth hormone axis augmentation as a strategy in this research area, identifying GHRH analogues as candidate compounds. Animal model work in rats using a forelimb chronic denervation design measured axon density, axon diameter, myelin thickness, neuromuscular junction reinnervation rates, and muscle fiber cross-sectional area following growth hormone axis intervention. Tesamorelin has been named in funded preclinical research programs examining axonal regeneration and muscle atrophy endpoints following nerve injury and repair in animal models.
GH/IGF-1 Axis and Endocrine Research
Reduced growth hormone secretion is documented in specific research populations, and review literature has characterized the altered GH/IGF-1 axis dynamics associated with those states. Tesamorelin is used in study designs testing whether upstream receptor-level stimulation produces different biochemical and body composition outcomes than direct growth hormone administration. Research in populations with reduced GH secretion and excess abdominal adiposity has measured visceral adipose tissue and liver transaminase endpoints over 12-month periods.
Neurochemical and Cognitive Research
GHRH analogues have been studied in randomized controlled designs measuring neurochemical and cognitive testing endpoints. A 20-week controlled trial conducted at the University of Washington School of Medicine assessed executive function, verbal memory, and visual memory composites in adults with mild cognitive impairment and in healthy older adults. A companion analysis using proton magnetic resonance spectroscopy measured brain gamma-aminobutyric acid (GABA), N-acetylaspartate, and myo-inositol levels in a subset of the same trial participants. These publications are the primary reference points for research examining GHRH signaling in the central nervous system.
Research Summary: What the Published Literature Shows
The tesamorelin literature is unusual among research peptides in its depth of controlled study design. Randomized, double-blind, placebo-controlled protocols with imaging and histology endpoints account for a large portion of the published record. Below is a summary of the main research areas.
| Research Area | Model | Reported Findings |
| Visceral Adipose Tissue | Randomized controlled trials, CT imaging | Reduction in CT-measured visceral adipose tissue over 26 and 52 week study periods versus placebo. |
| Hepatic Lipid Content | Randomized multicentre trial, MRI-PDFF with paired histology | Reduction in measured liver fat fraction and lower rate of fibrosis stage progression across 12 months. |
| Lipid and Glucose Markers | Pooled phase III analysis | Correlation between degree of visceral adipose reduction and changes in triglycerides, HDL, and insulin resistance indices. |
| Inflammatory Markers | Randomized controlled trial subanalysis | Measured relationship between inflammatory marker behavior and visceral adipose tissue reduction. |
| GH/IGF-1 Axis | Endocrine review and controlled trials | IGF-1 elevation used as the primary biochemical readout of GHRH receptor engagement. |
| Peripheral Nerve Regeneration | Rat chronic denervation models, review literature | Measured axon density, myelin thickness, neuromuscular junction reinnervation, and muscle fiber area in animal models of GH axis augmentation. |
| Neurochemical Endpoints | 20-week randomized controlled trial, MR spectroscopy | Measured brain GABA, N-acetylaspartate, and myo-inositol levels; executive function and verbal memory composites assessed in a parallel analysis. |
A pharmaceutical formulation of tesamorelin holds regulatory approval in the United States for a single narrow indication under a prescription drug label. That approval applies to a specific licensed pharmaceutical product and has no bearing on the material sold on this page. Tesamorelin supplied by AZOTH is a research chemical, is not a drug product, and is not supplied for any human or veterinary application. The clinical literature referenced above is provided as scientific background for laboratory researchers reviewing the published record.
Why Researchers Choose AZOTH for Tesamorelin
Reproducible laboratory research depends on knowing exactly what is in the vial. AZOTH supplies tesamorelin manufactured to strict purity specifications with third-party certificate of analysis documentation for every batch.
- Verified 99%+ purity by HPLC testing
- USA-manufactured under controlled quality protocols
- Third-party tested for identity, purity, and stability
- Lyophilized powder format for shelf stability
- Certificate of Analysis available for every batch
- Mass spectrometry confirmation of molecular weight
Whether your laboratory work centers on adipose tissue signaling, hepatic lipid pathways, GH/IGF-1 axis behavior, or nerve regeneration models, AZOTH supplies material that meets the documentation standards researchers and science-focused customers expect.
Storage and Handling
Tesamorelin is supplied as a lyophilized (freeze-dried) powder. Store at 2 to 8°C in a cool, dry environment away from direct light and moisture. For long-term storage, keep at -20°C. After reconstitution with bacteriostatic water, keep refrigerated at 2 to 8°C and use in accordance with your laboratory research protocol. Avoid repeated freeze-thaw cycles. Stability is maintained for up to 24 months when stored correctly in lyophilized form.
Legal Disclaimer
Tesamorelin sold by AZOTH is intended for laboratory and in vitro research use only. It is not approved by the Food and Drug Administration (FDA) for human consumption, medical use, diagnostic procedures, or veterinary use. This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Bodily introduction of any kind into humans or animals is strictly prohibited by law. All purchasers must be licensed researchers or qualified laboratory professionals. By purchasing this product, you acknowledge that you are aware of the applicable regulations in your jurisdiction and that you will use this compound exclusively within a qualified research environment.
| Research Findings | Journal | Data | Source Link |
| 1. Falutz J, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” | N. Engl. J. Med. | 2007; 357(23): 2359-2370. | https://pubmed.ncbi.nlm.nih.gov/18057338/ |
| 2. Falutz J, et al. “Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.” | J. Clin. Endocrinol. Metab. | 2010; 95(9): 4291-4304. | https://pubmed.ncbi.nlm.nih.gov/20554713/ |
| 3. Stanley TL, et al. “Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.” | Clin. Infect. Dis. | 2012; 54(11): 1642-1651. | https://pubmed.ncbi.nlm.nih.gov/22495074/ |
| 4. Stanley TL, et al. “Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.” | AIDS | 2011; 25(10): 1281-1288. | https://pubmed.ncbi.nlm.nih.gov/21516030/ |
| 5. Mangili A, et al. “Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat.” | PLoS One | 2015; 10(10): e0140358. | https://pubmed.ncbi.nlm.nih.gov/26457580/ |
| 6. Stanley TL, et al. “Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.” | Lancet HIV | 2019; 6(12): e821-e830. | https://pubmed.ncbi.nlm.nih.gov/31611038/ |
| 7. Rochira V, Guaraldi G. “Growth hormone deficiency and human immunodeficiency virus.” | Best Pract. Res. Clin. Endocrinol. Metab. | 2017; 31(1): 91-111. | https://pubmed.ncbi.nlm.nih.gov/28477736/ |
| 8. Tuffaha SH, et al. “Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury.” | Expert Opin. Ther. Targets | 2016; 20(10): 1259-1265. | https://pubmed.ncbi.nlm.nih.gov/27192539/ |
| 9. Lopez J, et al. “Growth hormone improves nerve regeneration, muscle re-innervation, and functional outcomes after chronic denervation injury.” | Sci. Rep. | 2019; 9: 3117. | https://pubmed.ncbi.nlm.nih.gov/30816300/ |
| 10. Baker LD, et al. “Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.” | Arch. Neurol. | 2012; 69(11): 1420-1429. | https://pubmed.ncbi.nlm.nih.gov/22869065/ |
| 11. Friedman SD, et al. “Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging.” | JAMA Neurol. | 2013; 70(7): 883-890. | https://pubmed.ncbi.nlm.nih.gov/23689947/ |
| 12. Makimura H, et al. “Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.” | J. Clin. Endocrinol. Metab. | 2012; 97(12): 4769-4779. | https://pubmed.ncbi.nlm.nih.gov/23015655/ |
| 13. Fourman LT, et al. “Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.” | AIDS | 2017; 31(16): 2253-2259. | https://pubmed.ncbi.nlm.nih.gov/28832410/ |
Featured Research Compounds
Original price was: $100.00.$90.00Current price is: $90.00.
Original price was: $100.00.$90.00Current price is: $90.00.
Original price was: $100.00.$90.00Current price is: $90.00.
Original price was: $100.00.$90.00Current price is: $90.00.
Research use only
All AZOTH products are intended solely for laboratory research, analytical, and scientific use. Products are not for human consumption, human use, veterinary use, diagnostic use, therapeutic use, or administration of any kind.